David Kerr
Founder at Oxford Cancer Biomarkers Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Nick la Thangue | M | - |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | 12 years |
Declan Doogan | M | 72 |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | - |
James Noble | M | 65 |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
Bernard J. Taylor | M | 67 |
University of Oxford
| - |
Nick Dixon-Clegg | M | - |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
Bill Fleming | M | - |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
Ian Gardiner | M | - |
University of Oxford
| - |
Collette Coll | M | - |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
Simon Kerry | M | 61 |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
Peter Grindrod | M | - |
University of Oxford
| - |
Robin Hanson | M | - |
University of Oxford
| - |
Judith Patricia Armitage | M | - |
University of Oxford
| - |
George Radda | M | - |
University of Oxford
| - |
Peter Hunter | M | - |
University of Oxford
| - |
Anil Razdan | M | 75 |
University of Oxford
| - |
Ngaire Woods | F | 62 |
University of Oxford
| 14 years |
Jayne Almond | F | 67 |
University of Oxford
| - |
Sangwoon Lee | M | - |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | - |
Ashok Kumar Bhattacharya | M | 78 |
University of Oxford
| - |
Peter Friend | M | - |
University of Oxford
| - |
André Finn | M | - |
University of Oxford
| - |
Jeff Orenstein | M | - |
University of Oxford
| - |
Katherine Mary Barker | F | 66 |
University of Oxford
| - |
Marcus du Sautoy | M | - |
University of Oxford
| - |
Robert Fry | M | - |
University of Oxford
| - |
Indrajit Wickramasinghe | M | - |
University of Oxford
| - |
Stephen Pulman | M | - |
University of Oxford
| - |
Len Blavatnik | M | 66 |
University of Oxford
| - |
Joseph Thomis | M | 78 |
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | 12 years |
Robert MacLaren | M | 57 |
University of Oxford
| - |
Richard Taylor | M | - |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | - |
Richard Taylor | M | - |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
Tae Park Sang | M | - |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | - |
Sheila Barrett | F | - |
University of Oxford
| - |
Hearth Henrietta | F | - |
University of Oxford
| 3 years |
Mee Lee Kyoung | M | - |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | - |
Chas Bountra | M | 64 |
University of Oxford
| - |
Sangwoo Lee | M | 52 |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | 8 years |
Li Jin | M | 54 |
University of Oxford
| - |
J. Doyne Farmer | M | 72 |
University of Oxford
| - |
Stefan Karl Neubauer | M | - |
University of Oxford
| - |
Zhan Feng Cui | M | 62 |
University of Oxford
| - |
Lars Henrik Fugger | M | 64 |
University of Oxford
| 17 years |
Maria Damanaki | F | 72 |
University of Oxford
| - |
Robyn Norton | F | - |
University of Oxford
| - |
Stephen MacMahon | M | - |
University of Oxford
| - |
Erik Anders Boman | M | 61 |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | - |
Leonard Charles William Seymour | M | 66 |
University of Oxford
| - |
Mike Chalfen | M | - |
University of Oxford
| - |
Matthew David Robson | M | 55 |
University of Oxford
| - |
Stephen Westaby | M | - |
University of Oxford
| - |
William Scott-Jackson | M | - |
University of Oxford
| - |
Ronald Daniel | M | - |
University of Oxford
| - |
Soo Min Yeoh | F | 68 |
University of Oxford
| - |
Anthony Charles Hotson | M | 70 |
University of Oxford
| - |
Stephen Davies | M | 74 |
University of Oxford
| 28 years |
Bill Spitz | M | 72 |
University of Oxford
| - |
Patrick Pichette | M | 61 |
University of Oxford
| - |
Tiong Lu Koh | M | 68 |
University of Oxford
| - |
Herman Waldmann | M | - |
University of Oxford
| - |
Peter Thompson | M | 64 |
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | - |
Robert Charles Wigley | M | 63 |
University of Oxford
| - |
Robert J. Champion de Crespigny | M | - |
University of Oxford
| - |
Lai Kuen Louey | M | 64 |
University of Oxford
| 13 years |
Stephen George Franklin | M | 77 |
University of Oxford
| - |
Barden N. Gale | M | 73 |
University of Oxford
| - |
Alan J. Kingsman | M | 73 |
University of Oxford
| - |
Victor Blank | M | - |
University of Oxford
| - |
William Castell | M | 76 |
University of Oxford
| - |
Crispin Davis | M | 75 |
University of Oxford
| - |
Raj Bhikhu Parekh | M | 63 |
University of Oxford
| - |
Vivian Liu | F | 62 |
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | - |
William R. Miller | M | 95 |
University of Oxford
| - |
David M. Upton | M | 64 |
University of Oxford
| - |
Wenn Sun | M | - |
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | - |
John Bell | M | 71 |
University of Oxford
| 35 years |
Alan J. Edwards | M | - |
University of Oxford
| - |
Dean Marc Slagel | M | 54 |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | - |
Leonard W. Seymour | M | - |
University of Oxford
| - |
Peter Ratcliffe | M | 69 |
University of Oxford
| - |
E. Kristine Klavers | F | - |
University of Oxford
| - |
John Hagan Pryce Bayley | M | - |
University of Oxford
| 21 years |
Wendy Becker | F | 58 |
University of Oxford
| - |
Alan Moore | M | - |
University of Oxford
| - |
Patrick Thomas | M | 67 |
University of Oxford
| - |
John Martin O'Loan | M | - |
University of Oxford
| - |
David Kirn | M | 62 |
University of Oxford
| - |
Marc Feldmann | M | 79 |
University of Oxford
| 13 years |
André S. Hoffmann | M | 66 |
University of Oxford
| - |
Geert Linnebank | M | 68 |
University of Oxford
| - |
Nigel Shadbolt | M | 68 |
University of Oxford
| - |
Michael Sydney Perry | M | - |
University of Oxford
| - |
Li Jin | M | 53 |
University of Oxford
| 12 years |
Alex Hawker | M | - |
University of Oxford
| - |
Simon Boddie | M | 64 |
University of Oxford
| 3 years |
Horace Deets | M | - |
University of Oxford
| - |
Adrian V. S. Hill | M | - |
University of Oxford
| - |
Matthew Frohn | M | - |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | - |
Lionel Tarassenko | M | 67 |
University of Oxford
| 27 years |
Jane Green | M | - |
University of Oxford
| - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 96 | 96.00% |
Cayman Islands | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Kerr
- Personal Network